Press release on Annual Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026.
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.3 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
HCG reported strong FY26 results with consolidated revenue growing 15% to Rs 25,454 Mn from Rs 22,228 Mn in FY25. Adjusted EBITDA rose 19% to Rs 4,711 Mn with margins expanding to 18.5% from 17.8%. PAT grew 25% to Rs 557 Mn (normalized for one-time exceptional items related to new labour code impact and goodwill impairment). Q4 FY26 was particularly strong with PAT jumping 363% YoY to Rs 341 Mn and EBITDA margins at 19.2%. The company successfully completed a Rs 4,250 Mn rights issue during the year, strengthening its financial position for capacity expansion and technology investments. HCG operates 25 hospitals across India and Africa under its cancer care brand.
Strong operational performance with margin expansion and profit growth demonstrates the scalability of HCG's cancer-focused model. The completed rights issue provides additional firepower for expansion while maintaining financial discipline, which could support the stock in the near term.